Phase 2 - Feasibility Study of supplemental area Clinical Trial Manufacturing Facility (CTMF)

As part of the Government of Canada's policy to develop vaccine expertise in Canada, the NRC is mandated to build a manufacturing plant for clinical batches of vaccines of different types. A first phase was completed in 2023 and consisted of the construction of a vaccine manufacturing facility (see attached drawings). The second phase consists of adding a viral vector ball room on the first floor, an mNRA vaccine production suite and a Quality Control Laboratory on the second floor of an existing building, the project includes all necessary utilities needed for the scope of work: ? Complete the viral vector manufacturing ball room, room 157 with an area of 112 m2, ? Add a mNRA vaccine production suite using part of room 210 with an area of 278,5 m2, ? Add a Quality Control Laboratory (Chemistry and Microbiology) in room 210 if possible or in a building extension, ? Add necessary services and utilities needed to produce the vaccines in the new production areas, ? Production rooms and utilities required will follow the following standards: o Health Canada Good Manufacturing Practices (GMP) o FDA Current Good Manufacturing Practices (cGMP) o Eudralex GMP standards